Key result
PON2 overexpression reduces ovarian tumor weight ~37% versus controls in a mouse xenograft model.
Why the study?
The role of Paraoxonase 2 (PON2) in ovarian cancer development remains unknown despite its known antioxidant properties and impact on mitochondrial ROS.
Does PON2 overexpression prevent tumor formation in a mouse model of ovarian cancer?
Does PON2 overexpression prevent tumor formation in a mouse model of ovarian cancer?
PON2 acts as a tumor suppressor in early-stage ovarian cancer by reducing mitochondrial superoxide generation and IGF-1 signaling, suggesting a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
Attenuates ovarian xenograft tumor growth; leaves open whether PON2 is a viable therapeutic target in patients.
Ovarian cancer (OC) is most lethal malignancy among all gynecological cancer. Large bodies of evidences suggest that mitochondrial-derived ROS play a critical role in the development and progression of OC. Paraoxonase 2 (PON2) is a membrane-associated lactonase with anti-oxidant properties. PON2 deficiency aggravates mitochondrial ROS formation, systemic inflammation, and atherosclerosis. The role of PON2 in cancer development remains unknown. In this report, in human, we identified that PON2 expression is higher in early stages (but not in late stages) of OC when compared to normal tissue. Using a mouse xenograft model of OC, we demonstrate that overexpression of PON2 prevents tumor formation. Mechanistically, PON2 decreases OC cell proliferation by inhibiting insulin like growth factor-1 (IGF-1) expression and signaling. Intriguingly, PON2 reduces c-Jun-mediated transcriptional activation of IGF-1 gene by decreasing mitochondrial superoxide generation. In addition, PON2 impairs insulin like growth factor-1 receptor (IGF-1R) signaling in OC cells by altering cholesterol homeostasis, which resulted in reduced caveolin-1/IGF-1R interaction and IGF-1R phosphorylation. Taken together, we report for the first time that PON2 acts as a tumor suppressor in the early stage of OC by reducing IGF-1 production and its signaling, indicating PON2 activation might be a fruitful strategy to inhibit early stage ovarian tumor.
No takes yet. Share an insight, caveat, or question.
Devarajan et al. (2018) studied Ovarian cancer (n=30). Paraoxonase 2 (PON2) overexpression vs. Empty vector (ID8 EV) was evaluated on Tumor weight (mg) (p=<0.01). Overexpression of human PON2 in a mouse xenograft model of ovarian cancer reduced tumor weight and volume compared to empty vector controls.
Synapse has enriched 10 related papers. Consider them for comparative context: